PCSK9 inhibitor valuation: A science ‐based review of the two recent models
Low‐density lipoprotein cholesterol (LDL‐C) has been extensively evaluated. Prospective cohort studies, randomized controlled trials, biology, pathophysiology, genetics, and Mendelian randomization studies, have clearly taught us that LDL‐C causes atherosclerotic cardiovascular disease. The newest class of drugs to lower LDL‐C, the proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, have been found to safely reduce LDL‐C approximately 60% when added to high‐intensity statin therapy. Because their cost is much greater than that of the currently available agents, their value has been ques...
Source: Clinical Cardiology - March 7, 2018 Category: Cardiology Authors: Seth J. Baum, Christopher P. Cannon Tags: REVIEW Source Type: research
The role of imaging in women with ischemic heart disease
Clinical Cardiology,Volume 41, Issue 2, Page 194-202, February 2018. (Source: Clinical Cardiology)
Source: Clinical Cardiology - March 5, 2018 Category: Cardiology Source Type: research
---
Clinical Cardiology,Volume 41, Issue 2, Page 194-202, February 2018. (Source: Clinical Cardiology)
Source: Clinical Cardiology - March 5, 2018 Category: Cardiology Source Type: research
Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive coronary artery disease)
Clinical Cardiology,Volume 41, Issue 2, Page 185-193, February 2018. (Source: Clinical Cardiology)
Source: Clinical Cardiology - March 2, 2018 Category: Cardiology Source Type: research
---
Clinical Cardiology,Volume 41, Issue 2, Page 185-193, February 2018. (Source: Clinical Cardiology)
Source: Clinical Cardiology - March 2, 2018 Category: Cardiology Source Type: research
